Physician profile
Michael Luu
NPI 1962963223
$4,884.78
in general payments reported to CMS, 2019-2025
14 companies · $722 in 2025
The $722 reported for 2025 was more than what 93% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,774 · 2024: $2,389 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,676 · Travel and Lodging: $1,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,676.49 |
| Travel and Lodging | $1,208.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,402.20 | 2023-2024 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, Intracept |
| Medtronic, INC. | $1,169.16 | 2023-2025 | Vanta Adaptivestim, Synchromedii, Intellis Adaptivestim |
| Globus Medical, INC. | $263.79 | 2025 | Senza |
| Nevro Corp. | $241.51 | 2023-2024 | Senza |
| Nalu Medical, INC. | $219.93 | 2024 | Nalu Neurostimulation System |
| Merck Sharp & Dohme LLC | $133.58 | 2025 | Winrevair |
| Tersera Therapeutics LLC | $124.29 | 2024 | Prialt |
| Mml US, INC. | $123.85 | 2023 | Reactiv8 |
| Spr Therapeutics, INC | $60.50 | 2023 | Sprint Pns System |
| Vertex Pharmaceuticals Incorporated | $58.02 | 2025 | |
| Bioventus LLC | $26.92 | 2025 | Durolane |
| Pfizer INC. | $22.18 | 2025 | |
| Depuy Synthes Sales INC. | $21.15 | 2025 | Monovisc |
| Abbvie INC. | $17.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.